Pamela M Holland

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. doi request reprint Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, AMA1 7 L 12, Cambridge, MA 02142 Electronic address
    Cancer Lett 332:156-62. 2013
  2. ncbi request reprint RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation
    Pamela Holland
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    Curr Biol 12:1424-8. 2002
  3. ncbi request reprint Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
  4. doi request reprint RIP4 regulates epidermal differentiation and cutaneous inflammation
    Ryan B Rountree
    Department of Oncology, Amgen, Seattle, Washington, USA
    J Invest Dermatol 130:102-12. 2010
  5. ncbi request reprint Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2
    Pamela M Holland
    Immunex Corporation, Seattle, Washington 98101, USA
    J Biol Chem 277:16229-40. 2002

Collaborators

Detail Information

Publications5

  1. doi request reprint Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, AMA1 7 L 12, Cambridge, MA 02142 Electronic address
    Cancer Lett 332:156-62. 2013
    ..In this review, current knowledge and new insights about Apo2L/TRAIL signaling is discussed with the focus on the development of Apo2L/TRAIL as a cancer therapeutic...
  2. ncbi request reprint RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation
    Pamela Holland
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    Curr Biol 12:1424-8. 2002
    ..Instead, abnormal hair follicle development and epidermal dysplasia, indicative of progression into a more pathologic state, are observed. Thus, RIP4 is a critical component of a novel pathway that controls keratinocyte differentiation...
  3. ncbi request reprint Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
    ....
  4. doi request reprint RIP4 regulates epidermal differentiation and cutaneous inflammation
    Ryan B Rountree
    Department of Oncology, Amgen, Seattle, Washington, USA
    J Invest Dermatol 130:102-12. 2010
    ..These data suggest that RIP4 functions in the epidermis through PKC-specific signaling pathways to regulate differentiation and inflammation...
  5. ncbi request reprint Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2
    Pamela M Holland
    Immunex Corporation, Seattle, Washington 98101, USA
    J Biol Chem 277:16229-40. 2002
    ..Treatment of cells with nocodazole leads to dramatic reorganization of Bicd2, and correlates with Nek8 phosphorylation. This may be indicative of a role for Nek8 and Bicd2 associated with cell cycle independent microtubule dynamics...